Medicine
fromNature
4 weeks agoTargeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors - Nature
Disrupting the cyclin A–E2F1 interaction selectively induces apoptosis in RB1/TP53-deficient small cell lung cancer, offering a synthetic lethal therapeutic strategy.